- JP-listed companies
- Cash flow
(4890) Cash flow
Market cap
¥5.6B
P/E ratio
Tsubota Lab develops innovative treatments for eye conditions like myopia, dry eye, and presbyopia, plus brain diseases, using research from Keio University.
| 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Depreciation & amortization | 3 | 14 | 38 | 39 | 36 | 29 | 21 |
| Cash from operations | 263 | 37 | 655 | 28 | -301 | -318 | -578 |
| Capital expenditures | -4 | -38 | -72 | -44 | -12 | -14 | -9 |
| Cash from investing | -4 | -44 | -72 | -54 | -12 | -15 | -8 |
| Proceeds from issuance of term debt, net | - | 250 | - | - | - | - | - |
| Repayments of term debt | -11 | -69 | -19 | -84 | -22 | -27 | -21 |
| Cash from financing | 19 | 237 | -19 | 1,012 | 36 | -12 | 17 |